Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Limited Stage Small Cell Lung Cancer

Interventions: Drug: tirapazamine
Drug: cisplatin
Drug: etoposide
Radiation: radiation therapy
Other: laboratory biomarker analysis

First Posted Date: 2003-08-07

Last Posted Date: 2014-05-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 72

Registration Number: NCT00066742

Locations: 🇺🇸
Southwest Oncology Group (SWOG) Research Base, San Antonio, Texas, United States

Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors

Not Applicable

Completed

Conditions: Childhood Germ Cell Tumor
Extragonadal Germ Cell Tumor

Interventions: Biological: bleomycin sulfate
Biological: filgrastim
Drug: cisplatin
Drug: cyclophosphamide
Drug: etoposide
Procedure: conventional surgery
Biological: MESNA

First Posted Date: 2003-08-07

Last Posted Date: 2013-10-17

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 19

Registration Number: NCT00066482

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Medical City Dallas Hospital, Dallas, Texas, United States
🇺🇸
Children's Memorial Hospital - Chicago, Chicago, Illinois, United States

and more 95 locations

Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Cisplatin
Drug: Etoposide
Radiation: Radiation therapy

First Posted Date: 2003-08-07

Last Posted Date: 2017-12-22

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 72

Registration Number: NCT00066222

Locations: 🇺🇸
Howard Community Hospital at Howard Regional Health System, Kokomo, Indiana, United States
🇺🇸
Kewanee Hospital, Kewanee, Illinois, United States
🇺🇸
OSF St. Francis Medical Center, Peoria, Illinois, United States

and more 101 locations

Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With Retinoblastoma

Phase 2

Completed

Conditions: Retinoblastoma

First Posted Date: 2003-07-18

Last Posted Date: 2011-10-04

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 4

Registration Number: NCT00004006

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor

Phase 2

Completed

Conditions: Neutropenia
Sarcoma

Interventions: Biological: filgrastim
Drug: amifostine trihydrate
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: ifosfamide
Drug: topotecan hydrochloride
Drug: vincristine sulfate
Procedure: conventional surgery
Radiation: low-LET cobalt-60 gamma ray therapy
Radiation: low-LET electron therapy
Radiation: low-LET photon therapy

First Posted Date: 2003-06-18

Last Posted Date: 2013-02-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 130

Registration Number: NCT00002643

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Medical City Dallas Hospital, Dallas, Texas, United States
🇺🇸
Long Beach Memorial Medical Center, Long Beach, California, United States

and more 46 locations

Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Leukemia
Lymphoma

First Posted Date: 2003-06-12

Last Posted Date: 2012-02-20

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Registration Number: NCT00018954

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇪🇬
National Cancer Institute of Egypt, Cairo, Egypt
🇮🇳
Kidwai Memorial Institute of Oncology, Bangalore, India

and more 2 locations

S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: cisplatin
Drug: docetaxel
Drug: etoposide
Procedure: conventional surgery
Radiation: radiation therapy

First Posted Date: 2003-06-06

Last Posted Date: 2013-11-25

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 46

Registration Number: NCT00062439

Locations: 🇺🇸
Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸
Holland Community Hospital, Holland, Michigan, United States
🇺🇸
Providence Cancer Institute at Providence Hospital - Southfield Campus, Southfield, Michigan, United States

and more 150 locations

Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors

Phase 2

Completed

Conditions: Sarcoma

Interventions: Drug: celecoxib
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: ifosfamide
Drug: vinblastine sulfate
Drug: vincristine sulfate
Procedure: conventional surgery
Radiation: radiation therapy
Drug: MESNA
Drug: Filgrastim

First Posted Date: 2003-06-06

Last Posted Date: 2019-02-15

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 38

Registration Number: NCT00061893

Locations: 🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
🇺🇸
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
Edwards Comprehensive Cancer Center at Cabell Huntington Hospital, Huntington, West Virginia, United States

and more 98 locations

Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

Phase 3

Completed

Conditions: Leukemia
Lymphoma

Interventions: Biological: filgrastim
Drug: cyclophosphamide
Drug: cytarabine
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: leucovorin calcium
Drug: etoposide
Drug: methotrexate
Drug: ifosfamide
Drug: vincristine sulfate

First Posted Date: 2003-05-21

Last Posted Date: 2013-08-21

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 83

Registration Number: NCT00005977

Locations: 🇺🇸
Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸
St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
🇺🇸
Texas Oncology P.A., Dallas, Texas, United States

and more 116 locations

High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors

Phase 2

Completed

Conditions: Breast Cancer
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Testicular Germ Cell Tumor
Unspecified Adult Solid Tumor, Protocol Specific
Unspecified Childhood Solid Tumor, Protocol Specific

First Posted Date: 2003-05-07

Last Posted Date: 2013-05-09

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 451

Registration Number: NCT00060255

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy